Chan Jack J, Tan Tira J Y, Dent Rebecca A
Division of Medical Oncology, National Cancer Center Singapore, Singapore.
Associate Professor, Division of Medical Oncology, National Cancer Center Singapore, 11 Hospital Drive, 169610, Singapore.
Ther Adv Med Oncol. 2019 Oct 9;11:1758835919880429. doi: 10.1177/1758835919880429. eCollection 2019.
Multiomic analyses have shed light upon the molecular heterogeneity and complexity of triple-negative breast cancers (TNBCs). With increasing recognition that TNBC is not a single disease entity but encompasses different disease subtypes, a one-size-fits-all treatment paradigm has become obsolete. In this context, the inhibition of phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) and androgen receptor (AR) signaling pathways have emerged as potential therapeutic strategies against selected tumors. In this paper, we reviewed the preclinical rationale, predictive biomarkers, efficacy, and safety data from early phase trials, and the future directions for these two biomarker-directed treatment approaches in TNBC.
多组学分析揭示了三阴性乳腺癌（TNBC）的分子异质性和复杂性。随着人们越来越认识到TNBC不是单一的疾病实体，而是包含不同的疾病亚型，一刀切的治疗模式已过时。在此背景下，抑制磷脂酰肌醇3激酶/蛋白激酶B（PI3K/AKT）和雄激素受体（AR）信号通路已成为针对特定肿瘤的潜在治疗策略。在本文中，我们综述了临床前理论依据、预测性生物标志物、早期试验的疗效和安全性数据，以及TNBC中这两种生物标志物导向治疗方法的未来方向。
